Background Although typically a late feature of gout, tophi may present early in the course of disease. The aim of this study was to identify factors associated with the presence of early ...

However, given the likely contribution of higher comorbidities to poorer health outcomes among respondents, comorbid status may be confounded with gout flares and tophi in the analyses.

Tophi are a symptom of gout. They are large, hardened masses of uric acid crystals within and around the joints. These masses can cause pain, joint deformity, and limited range of motion.

Recurring gout is often due to the deposition of urate crystals in bumps or nodules called tophi which generally are not painful but during flares of gout can become extremely painful. Those with ...

and dissolve tophi in gout and tophaceous gout patients, today announced the completion of enrollment for its pivotal global Phase 3 REDUCE 2 trial. "We would like to thank the gout community for ...

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...